Bronpass Tab.
ApprovedSmall molecule
Bronpass Tab. is one of 38 small molecule programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Approved.
2
Indications
2
Total Trials
1
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
557 competitors in Chronic Obstructive Pulmonary Disease
#DrugCompanyPhaseTrials
1Bronpass Tab.
HHanlim Pharm. Co., Ltd.
Approved
Veramyst
GSKPreclinical
Flovent
GSKPreclinical
Spiriva
Boehringer IngelheimPreclinical
Aclidinium Bromide
AstraZenecaPreclinical
Duragesic
CCephalon
Preclinical
Narcan
SScienture
Preclinical
Zoloft
VViatris Specialty LLC
Preclinical
Coumadin
AAbbott
Preclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Bronpass Tab.. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- HHanlim Pharm. Co., Ltd.